Verrica Pharmaceuticals (VRCA) Earnings Date, Estimates & Call Transcripts $6.72 -0.10 (-1.39%) As of 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Verrica Pharmaceuticals Earnings Summary Verrica Pharmaceuticals posted Q2 2025 earnings on August 12, 2025, reporting an EPS of $0.02, which beat analysts' consensus estimates of -$0.70 by $0.72. Quarterly revenue was reported to be $12.70 million, above the consensus estimate of $4.37 million. With a trailing EPS of -$8.28, Verrica Pharmaceuticals' earnings are expected to grow next year, from ($1.46) to ($0.74) per share. Latest Q2 Earnings DateAug. 12EstimatedConsensus EPS (Aug. 12) -$0.70 Actual EPS (Aug. 12) $0.02 Beat By $0.72 Actual Revenue (Aug. 12) $12.70MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get Verrica Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verrica Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataVRCA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VRCA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Verrica Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$1.00-$1.00-$1.00Q2 20252-$0.90-$0.70-$0.80Q3 20252-$0.70-$0.60-$0.65Q4 20252-$0.60-$0.20-$0.40 Verrica Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025-$0.70$0.02+$0.72$0.02$4.37M$12.70M5/13/2025Q1 2025-$1.40-$1.00+$0.40-$0.10$2.53M$3.44M3/11/2025Q4 2024-$2.50-$2.40+$0.10-$0.24$1.30M$0.34M11/4/2024--$3.70-$4.90 -$1.20-$0.49$7.53M-$1.78M8/14/2024Q2 2024-$4.30-$3.70+$0.60-$0.37$4.70M$5.18M5/13/2024Q1 2024-$5.40-$4.40+$1.00-$0.44$2.70M$3.83M2/29/2024Q4 2023-$4.70-$4.80 -$0.10-$0.43$1.10M$1.99M11/9/2023Q3 2023-$2.20-$3.20 -$1.00-$0.10$1.12M$2.92M Verrica Pharmaceuticals Earnings - Frequently Asked Questions When did Verrica Pharmaceuticals announce their last quarterly earnings? Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earning data on Tuesday, August 12, 2025. Learn more on VRCA's earnings history. Did Verrica Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Verrica Pharmaceuticals (NASDAQ:VRCA) reported $0.02 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.70) by $0.72. Learn more on analysts' earnings estimate vs. VRCA's actual earnings. How can I listen to Verrica Pharmaceuticals' earnings conference call? The conference call for Verrica Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read Verrica Pharmaceuticals' conference call transcript? The conference call transcript for Verrica Pharmaceuticals' latest earnings report can be read online. Read Transcript How much revenue does Verrica Pharmaceuticals generate each year? Verrica Pharmaceuticals (NASDAQ:VRCA) has a recorded annual revenue of $7.57 million. How much profit does Verrica Pharmaceuticals generate each year? Verrica Pharmaceuticals (NASDAQ:VRCA) has a recorded net income of -$76.58 million. VRCA has generated -$12.00 earnings per share over the last four quarters. What is Verrica Pharmaceuticals' EPS forecast for next year? Verrica Pharmaceuticals' earnings are expected to grow from ($1.46) per share to ($0.74) per share in the next year. More Earnings Resources from MarketBeat Related Companies CRGX Earnings Results YMAB Earnings Results EDIT Earnings Results ELDN Earnings Results MDWD Earnings Results AVTE Earnings Results ENGN Earnings Results CTMX Earnings Results EPRX Earnings Results VTYX Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? This page (NASDAQ:VRCA) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access